Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-23

FDA Approved: CAVERJECT — Supplemental Application (Pharmacia & Upjohn Company LLC)

View source ↗

Summary

FDA approved a supplemental application for CAVERJECT (alprostadil) submitted by Pharmacia & Upjohn Company LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CAVERJECT (ALPROSTADIL)

Snippet

SUPPL AP for CAVERJECT (ALPROSTADIL)